Galmed Pharmaceuticals (Galmed Pharmaceuticals) EV-to-EBIT : 1.37 (As of Apr. 26, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Galmed Pharmaceuticals's Enterprise Value is $-10.24 Mil. Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.49 Mil. Therefore, Galmed Pharmaceuticals's EV-to-EBIT for today is 1.37.

The historical rank and industry rank for Galmed Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

GLMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.03 Med: -0.44 Max: 5.86
Current: 1.37

During the past 12 years, the highest EV-to-EBIT of Galmed Pharmaceuticals was 5.86. The lowest was -19.03. And the median was -0.44.

GLMD's EV-to-EBIT is ranked better than
62.22% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs GLMD: 1.37

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Galmed Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-10.31 Mil. Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.49 Mil. Galmed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 72.70%.

Galmed Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Galmed Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals EV-to-EBIT Chart

Galmed Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-2.10

-0.52

-0.34

0.05

1.38

Galmed Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															0.05	0.10	0.37	1.39	1.38

Competitive Comparison of Galmed Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Galmed Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's EV-to-EBIT falls into.

Galmed Pharmaceuticals EV-to-EBIT Calculation

Galmed Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-10.242	/	-7.492
	=	1.37

Galmed Pharmaceuticals's current Enterprise Value is $-10.24 Mil.
Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.49 Mil.

Galmed Pharmaceuticals (NAS:GLMD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Galmed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-7.492	/	-10.3053794
	=	72.70 %

Galmed Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-10.31 Mil.
Galmed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.49 Mil.

Galmed Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

GPH:Germany

Address

16 Tiomkin Street, Tel Aviv, ISR, 6578317

Website

https://www.galmedpharma.com

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.